Darren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine

Size: px

Start display at page:

Download "Darren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine"

Rudolf Michael Dennis
6 years ago
Views:

1 Darren J. Bell, M.D. Education Texas A&M University College of Medicine College Station, Texas Doctor of Medicine Texas A&M University College Station, Texas Bachelor of Science, Biomedical Engineering Postgraduate Education Vitreoretinal Fellowship Charles Retina Institute Preceptor: Steve Charles, MD Memphis, Tennessee Ophthalmology Residency University of Tennessee Memphis, Tennessee Transitional Internship Methodist University Hospital Memphis, Tennessee Publications and Presentations 1. Singer MA, Bell DJ, Woods P, et al. Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitral Implant in Patients with Retinal Vein Occlusion. Retina Charles S and Bell DJ. Repositioning Dislocated Intraocular Lenses into the Anterior Chamber. Retina. 2008;7: Bell DJ and Chaum E. A 30 year old woman with gradual vision loss OU. Digital Journal of Ophthalmology. October < 4. Bell DJ and Wilson MW. Choroidal Melanoma: Natural History and Management Options. Cancer Control. 2004;11: Bell DJ and Walton RC. CMV Retinitis in the Era of HAART. (Presentation) University of Tennessee Residents Day, 6/ Bell DJ. Modern Vision Correction: LASIK and other methods. (Presentation) Methodist Hospital, 1/2002

2 Research Experience (Alcon Gate C-08-36) The Safety and Efficacy of Al-8309b Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age- Related Macular Degeneration (AMD) (Alcon C ) A safety and Efficacy Comparison of Travoprost Ophthalmic Solution % Administered 12 Times Daily to TRAVATAN 0.004% QD in Patients with Open-Angle Glaucoma or Ocular Hypertension (Allergan 001) A 12-Month, Multicenter, 2 Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO) (Allergan 011) A 3-Year, Phase 3, Multi-Center, Masked, Randomized, Sham- Controlled Trial to Assess the Safety and Efficacy of 700 ug and 350 ug of Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema (Allergan 018) A 26 Week, Open-Label Study to Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema (DME) (Allergan 019) A 26 Week, Open-Label Study to Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Drug Delivery System Applicator System in Conjunction with Lucentis in the Treatment of Patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (Allergan 030D) A Multi-center, Masked, Randomized, Sham-controlled, Parallelgroup, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator system in Patients with Primary Open-Angle Glaucoma (Allergan 031D) A Multicenter, Masked, Randomized, sham-controlled, Parallelgroup, 3 month Study with a 9-Month Safety Extension to

3 Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Improving Visual function in Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment (Allergan 032D) A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus12 Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Geographic Atrophy from Age-Related Macular Degeneration (Allergan 033D) A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System (Allergan 041D) A Multicenter, Paired-Eye Comparison, Dose-Escalation, Single Dose, 24-Month Study of Safety and Efficacy of Bimatoprost Preservative Free Intracameral Drug Delivery System (Bimatoprost PF IC DDS) in Patients with Open-Angle Glaucoma (Allergan Pyramid PPV GMA-OZU ) A 1-Month, Multicenter, Observational Study to Evaluate the Degree of Ocular Inflammation Associated with Pars Plana Vitrectomy (Covance/Fovea Pharmaceutical SA FOV2304/CLIN/201/P) A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Centerinvolving Clinically Significant Macular Edema Associated with Diabetic Retinopathy (DRCRnet-Protocol N) An evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (Protocol N) (Genentech BRAVO) A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion

4 (Genentech CRUISE) A Phase III, Multicenter, Randomized, Sham Injections- Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (Genentech Horizon RVO) An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech Sponsored Ranibizumab Study (Genentech FVF4170g-Rise) A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus (Genentech FVF4579g-Harbor) A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As- Needed Basis (PRN) in Patients with Subfoveal Neovascular Age- Related Macular Degeneration (Genentech FVF4967g-Shore) A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion (Genentech-Galley) GALLEY-Genetic Assessment of early to Late Macular Degeneration study (Genentech IND Compass) Clinical Assessment of Age-Related macular Degeneration Patients After Early Diagnosis and Treatment with Ranibizumab (Genentech-Seven Up) SEVEN year Observational Update of Macular Degeneration Patients Post- MARINA/ANCHOR and HORIZON trials (MacuSight-Diamond) A Phase 2, Randomized, Double-Masked, Placebo-Controlled,

5 Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy (MacuSight-Emerald) A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis Plus Sirolimus Versus Lucentis Plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (NAION/Eli Lilly-Kendle) A Prospective Case-Crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NeoVista-Cabernet) A Randomized, Prospective, Active Controlled, Study of the Epi- Rad Ophthalmic System for the for the Treatment of Subfoveal Choroidal Neovasculariation Associated with Wet Age-Related Macular Degeneration (NeoVista-Rose) A Feasibility Study to Evaluate the Safety and Tolerability of the Epi-Rad Ophthalmologic of Subfoveal Choroidal Neovascularization (CNV) in Patient with Age Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy (Optos) Investigator Sponsored Using Optos Machine in the Anti-VEGF/OZURDEX Combination Trial (OZURDEX) Investigator Sponsored OZURDEX as an Adjunctive Therapy to Anti-VEGF in Patients with Retinal Vein Occlusion (RVO) (Regeneron VGFT-OD-0605/VIEW 1) A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age- Related Macular Degeneration (Regeneron VGFT-OD-0702) A Randomized, Single-Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap Eye in Subjects with Neovascular VEGF Trap-Eye in Subjects with Neovascular Age- Related Macular Degeneration

6 (Regeneron VGFT-OD-0819/Copernicus) A Randomized, Double-Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (Regeneron VGFT-OD-1009/VISTA) A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-eye in Patients with Diabetic Macular Edema (Santen DE-109/32-007/Uveitis) A Phase III, Multinational, Multicenter, Randomized, Double- Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye (Thrombogenics/MiviTrust) A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion (Receptos, Inc.- RPCS 001) A Phase 1, Single Center, Randomized, Double-Blind, Placebo- Controlled Single and Multiple Dose Safety, Tolerability, Pharmacokinetic Pharmcodynamic Study of Orally Administered RPC1063 in Health Volunteers Professional memberships Work Experience American Academy of Ophthalmology American Society of Retinal Specialists Texas Ophthalmological Association Medical Center Ophthalmology Associates San Antonio, Texas 2008-present University of Tennessee, Department of Ophthalmology Clinical Instructor Community activities Hobbies Soccer coach Boerne Soccer Club, I9 sports Golf, tennis, furniture building, home improvement

7 Awards received Outstanding Resident Teaching Award: 2006 Cum Laude Graduate: 1996 Harold W. Gaines Excellent Service Award: 1996 MSC OPAS Maestro Award: 1996 MSC OPAS Outstanding Director Award: 1996 Tau Beta Pi Engineering Honor Society: 1995 Alpha Eta Mu Beta Biomedical Engineering Honor Society: 1995 Phi Eta Sigma Freshman Honor Society : 1993 Engineering Scholars Program: Dean s Honor Award

Brett Taylor Foxman, M.D.

Brett Taylor Foxman, M.D. Address: 1500 Tilton Road Northfield, New Jersey 08225 Tel: (609) 646-5200 Fax: (609) 646-9868 E-mail: bfoxman@retina.com Primary Activities: Retina Specialist Retinal and Ophthalmic